We’re a finalist for the Nordic Startup Awards Best HealthTech 2023. Vote for Abzu! →

Case study:

Abzu helped discover biomarkers for a successful clinical trial.

We explored genes and gene-signature interactions to identify and explain treatment responses with Checkmate Pharmaceuticals.

Understanding which factors drive outcomes – and how they’re related – is a clear advantage for successful clinical trials.

Revealing the hidden drivers in diseases, drugs, and patients.

We supported a single Computational Biologist with expertise in target discovery and target validation in oncology.

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.

Why Abzu?

Because traditional machine learning techniques don’t deliver enough actionable insights for scientists and researchers.

Our technology and service offerings are flexible. We can help you identify novel relationships and relevant pathways – even in small data sets – resulting in a set of composite biomarker signatures.

Technology and services.

Abzu’s flexible offerings include our proprietary AI discovery engine, the QLattice®, data access and processing, and regulatory compliance and approval.

The Abzoids on the team.

Abzu’s personalized bioinformatic services are led by PhD-level scientists.

Share this case study.

Start a conversation.

Every team, project, and pipeline is unique, and we want to hear about yours.

Contact us any way you like — email, phone, or online form — or schedule a one-on-one with a scientist.

Subscribe for notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.

Share this case study.